The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Actuate Therapeutics Inc shares valued at $499,996 were purchased by Bios Equity COF, LP on Jun 27 ’25. At $7.00 per share, Bios Equity COF, LP acquired 71,428 shares. The insider’s holdings grew to 196,428 shares worth approximately $1.23 million following the completion of this transaction.
Also, Kreis Leslie W. purchased 71,428 shares, netting a total of over 499,996 in proceeds. Following the buying of shares at $7.00 each, the insider now holds 196,428 shares.
Before that, Fletcher Aaron G.L. had added 71,428 shares to its account. In a trade valued at $499,996, the Director bought Actuate Therapeutics Inc shares for $7.00 each. Upon closing the transaction, the insider’s holdings increased to 71,428 shares, worth approximately $1.23 million.
As published in their initiating research note from Craig Hallum on April 22, 2025, Actuate Therapeutics Inc [ACTU] has been a Buy and the price target has been revised to $21. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in mid March.
Analyzing ACTU Stock Performance
On last trading session,, Actuate Therapeutics Inc [NASDAQ: ACTU] rose 0.48% to $6.26. The stock’s lowest price that day was $6.0, but it reached a high of $7.33 in the same session. During the last five days, there has been a surge of approximately 1.29%.
Support And Resistance Levels for Actuate Therapeutics Inc (ACTU)
RSI (Relative Strength Index) is 39.71 on the 14-day chart, showing neutral technical sentiment.
Is Actuate Therapeutics Inc subject to short interest?
Stocks of Actuate Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 43087.0 shares to 0.24 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 0.2 million shares. A jump of 17.85% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.74 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.74.
Which companies own the most shares of Actuate Therapeutics Inc (ACTU)?
In terms of Actuate Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 21 in the next 12 months, up nearly 237.08% from the previous closing price of $6.23. Analysts anticipate Actuate Therapeutics Inc stock to reach 21 by 2025, with the lowest price target being 21.
